About: Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. Patients and Methods: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. Results: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). Conclusion: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib. Background: Tumor biomarkers are used for predicting therapy effect and prognosis of patients with non-small cell lung cancer (NSCLC). We focused on their potential role in prediction of the efficacy of erlotinib. Patients and Methods: In a total of 144 patients with advanced-stage (IIIB or IV) NSCLC treated with erlotinib, pre-treatment levels of soluble carcinoembryonic antigen (CEA) and cytokeratin markers in serum were measured. Results: The median progression-free and overall survival for patients with a high level of carcinoembryonic antigen (CEA) was 1.9 and 8.6 vs. 2.9 and 16.1 months for patients with low CEA (p=0.046 and p=0.116). The respective medians for patients with a high level of cytokeratin-19 fragment were 1.9 and 6.1 vs. 3.4 and 23.8 months for patients with the low cytokeratin-19 fragment (p<0.001 and p<0.001). Conclusion: High pre-treatment serum levels of one or both biomarkers are associated with poor outcome of patients with NSCLC treated with erlotinib. (en)
Title	Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib (en)
skos:prefLabel	Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib (en)
skos:notation	RIV/00216208:11140/14:10271887!RIV15-MSM-11140___
http://linked.open...avai/riv/aktivita	I P
http://linked.open...avai/riv/aktivity	I, P(NR9087)
http://linked.open...iv/cisloPeriodika	6
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Topolčan, Ondřej Fiala, Ondřej Pešek, Miloš Fínek, Jindřich
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / Lékařská fakulta v Plzni
http://linked.open...dnocenehoVysledku	38780
http://linked.open...ai/riv/idVysledku	RIV/00216208:11140/14:10271887
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	prediction; EGFR-TKI; NSCLC; erlotinib; CYFRA 21-1; CEA; Tumor marker (en)
http://linked.open.../riv/klicoveSlovo	EGFR-TKI CEA Tumor marker prediction CYFRA 21-1 NSCLC erlotinib
http://linked.open...odStatuVydavatele	GR - Řecká republika
http://linked.open...ontrolniKodProRIV	[0B49BC406E31]
http://linked.open...i/riv/nazevZdroje	Anticancer Research
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	4 (xsd:int)
http://linked.open...cetTvurcuVysledku	7 (xsd:int)
http://linked.open...vavai/riv/projekt	Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	34
http://linked.open...iv/tvurceVysledku	Benešová, Lucie Bortlíček, Zbyněk Fiala, Ondřej Minárik, Marek Pešek, Miloš Topolčan, Ondřej Fínek, Jindřich
http://linked.open...ain/vavai/riv/wos	000336875200067
issn	0250-7005
number of pages	6 (xsd:int)
http://localhost/t...ganizacniJednotka	11140

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 41 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software